-+ 0.00%
-+ 0.00%
-+ 0.00%

VIR BIOTECHNOLOGY ANNOUNCES EXPANDED PHASE 2 SOLSTICE DATA FOR ELEBSIRAN AND TOBEVIBART IN CHRONIC HEPATITIS DELTA, SHOWING DEEP AND SUSTAINED VIRAL SUPPRESSION, AND EXPLORATORY FINITE TREATMENT DATA

Reuters·11/08/2026 21:45:00

Please log in to view news